PEGS

Twist Bioscience Highlights Synthetic Libraries and High Throughput Antibody Discovery Platform at PEGS Boston 2022

Retrieved on: 
Monday, May 2, 2022
Health, Biotechnology, CAR, Antibody, Proteinogenic amino acid, Epitope, VHH, U.S. Securities and Exchange Commission, Forward-looking statement, Private Securities Litigation Reform Act, Hynes Convention Center station, Agriculture, Immunoglobulin G, RNA transfection, Library, NASDAQ, SVP, Phoenix Carnegie Library and Library Park, Engineering, Martek Biosciences Corporation, Cell, NGS, Doctor of Philosophy, Patient, Twist Bioscience, Drug discovery, Gene editing, Risk, PEGS, ELISA, Therapy, Synthetic biology, Aircraft registration, Concurrent use registration, DNA, Genomics, ADORA2A, Hynes Convention Center, Security (finance), Silicon, TCR, Immunization, CRISPR, SEC, Hyperimmune, CEO, Protein, Technology, Biology, Humanized antibody, Vaccine, Antibiotics

These posters show the depth and breadth of the antibody discovery and library construction capabilities of Twist Biopharma against high-impact targets, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • These posters show the depth and breadth of the antibody discovery and library construction capabilities of Twist Biopharma against high-impact targets, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Our next generation libraries enable antibody discovery for therapies such as CAR-T engineered cell therapies, which have the potential to change the treatment landscape for patients.
  • In addition, the data presented on the discovery of an antibody targeting ADORA2A, a next generation checkpoint, demonstrate Twist Biopharmas ability to generate antibodies independently.
  • Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development.

iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants

Retrieved on: 
Monday, May 2, 2022
Antibody, Xylose, GLOBE, Company, Poster, Hamster, Glycosylation, Doctor of Philosophy, PEGS, CHO, CDMO, Rituximab, Vaccine, Neutralizing antibody, Plant, Fucose, Conference, SEC, Infection, Hydroponics, Protein, Cancer, Fine chemical

BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, announced today that it will present a poster at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Boston Conference & Expo, May 2-5.

Key Points: 
  • Rachel Jordan, PhD, a senior product manager at iBio, will present the poster (#P061), titled "Plant-Made Antibodies Show Superior Glycosylation Homogeneity While Retaining Pharmacokinetic Properties," which highlights:
    The production of a single uniform G0 glycosylation pattern, lacking fucose and xylose, of NISTmAb and rituximab when compared to Chinese Hamster Ovary (CHO) cell culture produced antibodies, which contain more heterogeneous glycosylation patterns.
  • Comparability of in vivo rodent pharmacokinetic profiles for NISTmAb and rituximab produced using mammalian cell culture and the FastPharming System.
  • How rapid, scalable transient expression in plants of high-quality mAbs for in vivo studies can significantly shorten the time to achieve in vivo proof-of-concept.
  • Its FastPharming System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins.

Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

Retrieved on: 
Tuesday, April 26, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, U.S. Securities and Exchange Commission, Security (finance), Research, Trichloroethylene, Patient, EGFR, Immune system, MCRPC, NHP, Tumor microenvironment, Large-cell lung carcinoma, NOAEL, FDA, SCCHN, Therapy, Metastasis, Cytokine release syndrome, Treatment, Head, TCE, PK, IND, PEGS, Food, Conference, Hematological Cancer Research Investment and Education Act, Fiat 500X, Neck, News, CEO, Pharmacokinetics, Toxicity, Half-life, PSMA, GMP, CD3, TME, NSCLC, Nasdaq, Hynes Convention Center, Safety, CRS, Cancer, GLP, 300X, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, CRC, Hynes Convention Center station, Risk, Vaccine, Pharmaceutical industry, Engineering plastic

The preclinical data to be presented for JANX007 and JANX008 at PEGS Boston is an important step forward for Januxs proprietary TRACTr technology platform and our pipeline of next-generation immunotherapies, said David Campbell, Ph.D., President, and CEO of Janux.

Key Points: 
  • The preclinical data to be presented for JANX007 and JANX008 at PEGS Boston is an important step forward for Januxs proprietary TRACTr technology platform and our pipeline of next-generation immunotherapies, said David Campbell, Ph.D., President, and CEO of Janux.
  • We look forward to advancing the IND submissions for both next-generation immunotherapies over the course of this year.
  • - Janux plans to submit an IND application for JANX008 with the FDA in the second half of 2022.
  • Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations by offering accuracy, stability, activity, modularity, and manufacturability.

SK*P CONTINUES ITS MISSION TO RID THE BEAUTY INDUSTRY OF ITS PLASTIC ADDICTION WITH NEW NATIONAL RETAIL PARTNERSHIP, THE SK*P SWAP INITIATIVE AND FOUNDER TOUR

Retrieved on: 
Tuesday, April 19, 2022
CEO, Board, Ulta, Awareness, Carbon, Forest, Climate change, Plant, Silicone, Scalp, Plastic, Greeting, Life, PEGS, CO2, Paraben, Education, Program, Kelp, Sale, Skin, BPA, Movement, Environment, Ecosystem, FSC, VOC, Sulfate, Ulta Beauty, Multimedia, Industry, Partnership, Hair, Health, Cosmetics

Introducing an exclusive retail partnership with Ulta Beauty, sk*p will now be available on Ulta.com and in more than 700 Ulta Beauty stores nationwide kicking off this April.

Key Points: 
  • Introducing an exclusive retail partnership with Ulta Beauty, sk*p will now be available on Ulta.com and in more than 700 Ulta Beauty stores nationwide kicking off this April.
  • The brand will also be included in SPARKED , a curated assortment of emerging beauty brands entering retail for the first time.
  • Furthermore, this month, sk*p will kick off a nationwide initiative asking consumers to make the 'sk*p Swap', trading in their plastic beauty bottle for the brand's BeautyCarton.
  • "Currently, the beauty industry contributes over 80 billion pieces of plastic waste to landfills and waterways each year.

IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 10, 2021
Dana, Population, Safety, SITC, SNO, TMZ, PEGS, Private Securities Litigation Reform Act, Graft-versus-host disease, Partner, Hematopoietic stem cell transplantation, Clinical trial, Methyltransferase, R, Security (finance), CEO, Congress, Temozolomide, Inc., GBM, DRI, HSCT, Society, Deltex Medical Group, NEW, COVID-19, MGMT, Research, Forward-looking statement, Scientific Reports, Cytokine release syndrome, Company, IPO, U.S. Securities and Exchange Commission, GLOBE, Board of directors, SEC, Research and development, Pathology, Dana–Farber Cancer Institute, Mouse, Immunotherapy, Survival, Nasdaq, Patient, Neurotoxicity, Risk, Leukemia, Glioblastoma, Pharmaceutical industry, Cryptocurrency, Fine chemical, Vaccine, Animal

NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced financial results and operational highlights for the third quarter ended September 30, 2021.

Key Points: 
  • NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced financial results and operational highlights for the third quarter ended September 30, 2021.
  • In July 2021, IN8bio appointed Emily Fairbairn and Luba Greenwood as two independent members of the Companys Board of Directors.
  • In August 2021, IN8bio closed its initial public offering, in which it issued and sold 4,000,000 shares of common stock at a public offering price of $10.00 per share.
  • In September 2021, IN8bio announced the peer-reviewed publication of preclinical results that it believes provides foundational support for the use of its DeltEx Drug Resistant Immunotherapy (DRI) in newly diagnosed GBM.

Gamida Cell Presents Data on its NAM-Enabled NK Cell Therapies at Protein & Antibody Engineering Summit (PEGS) Europe

Retrieved on: 
Thursday, November 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Lung, Cancer, Immunotherapy, RPMI, LinkedIn, PEGS, Twitter, CAR, BLA, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Security (finance), FDA, Allergy, Asthma & Immunology Research, Hereditary diffuse gastric cancer, Lymphatic system, Protein, Breast, CISH, SEC, Cell, CRISPR, NAM, Risk, Instagram, Research and development, Facebook, COVID-19, NK, Research, HER2, Therapy, K562, Hematology, Pharmaceutical industry, Medical imaging

Data presented by Gamida Cell demonstrated that the engineered GDA-501 NK enhances potency and cytotoxicity against a HER2-expressing tumor cell line.

Key Points: 
  • Data presented by Gamida Cell demonstrated that the engineered GDA-501 NK enhances potency and cytotoxicity against a HER2-expressing tumor cell line.
  • Data also showed that GDA-301 has cytotoxic activity against a chronic myelogenous leukemia cell line (K562) and a multiple myeloma cell line (RPMI).
  • The field of NK cell immunotherapy is advancing beyond what has previously been understood from T cell gene editing, said Yona Geffen, Ph.D., Vice President, Research and Development at Gamida Cell.
  • Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases.

Berkeley Lights to Present on Cell Line Development of Complex Molecules and Accelerating Antibody Discovery Against Difficult Targets at 13th Annual PEGS Europe

Retrieved on: 
Monday, November 1, 2021
Molecule, CHO, PEGS, Industry, Drug development, Workflow, Europe, Neutralizing antibody, Immortalised cell line, RESEARCH, UTC, Engineering, Ion, Antibody, U.S. Securities and Exchange Commission, B cell, FOR, Risk, Growth, G protein-coupled receptor, Cell, Trinidad and Tobago Securities and Exchange Commission, Nasdaq, GLOBE, Culture, CLD, Fine chemical, Vaccine

PEGS is one of the industrys most preeminent events that inspires accelerated biotherapeutic protein drug development.

Key Points: 
  • PEGS is one of the industrys most preeminent events that inspires accelerated biotherapeutic protein drug development.
  • Berkeley Lights scientists will lead two presentations at PEGS Europe in the Antibody Engineering and Cell Line Engineering tracks:
    Bringing Product Quality Assessment into Early Clone Selection with Opto Cell Line Development on November 2, 2021, from 12:25 p.m. 12:55 p.m. UTC+1.
  • The workflow accelerates early cell line development (CLD) by integrating high throughput cell sorting, cloning, culture, productivity, growth, and product quality assays into a single, five-day automated process.
  • Leave No Hit Behind: Accelerating Lead Molecule Discovery Against Difficult Targets, on Wednesday, November 3 from 9:30 a.m. 10:00 a.m. UTC +1.